Sexual well-being and diurnal cortisol after prostate cancer treatment.

Item request has been placed! ×
Item request cannot be made. ×
loading   Processing Request
Read More Add to Saved list
  • Additional Information
    • Source:
      Publisher: Sage Publications Country of Publication: England NLM ID: 9703616 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1461-7277 (Electronic) Linking ISSN: 13591053 NLM ISO Abbreviation: J Health Psychol Subsets: MEDLINE
    • Publication Information:
      Original Publication: London ; Thousand Oaks, CA : Sage Publications, 1996-
    • Subject Terms:
      Hydrocortisone* ; Prostatic Neoplasms*/therapy; Circadian Rhythm ; Humans ; Hypothalamo-Hypophyseal System ; Male ; Pituitary-Adrenal System ; Saliva
    • Abstract:
      Sexual dysfunction and psychological distress are common after prostate cancer. Research has not examined the role of neuroendocrine markers of stress (e.g. cortisol). This study examines whether sexual functioning or sexual bother is associated with diurnal cortisol. Men treated for prostate cancer completed the University of California-Los Angeles Prostate Cancer Index and provided saliva samples four times daily for cortisol assessment. Higher sexual bother, but not sexual functioning, was associated with steeper cortisol slope. Better sexual functioning, and not sexual bother, was significantly associated with the cortisol awakening response. Assessment of stress and stress-reducing interventions might be warranted in sexual rehabilitation after prostate cancer.
    • References:
      Endocrine. 2014 Aug;46(3):423-30. (PMID: 24705931)
      Psychoneuroendocrinology. 2013 Nov;38(11):2720-8. (PMID: 23890985)
      Neurosci Biobehav Rev. 2016 Sep;68:928-945. (PMID: 27377692)
      Psychoneuroendocrinology. 2003 Oct;28(7):916-31. (PMID: 12892658)
      Neurosci Biobehav Rev. 2010 Sep;35(1):97-103. (PMID: 20026350)
      N Engl J Med. 2008 Mar 20;358(12):1250-61. (PMID: 18354103)
      Psychoneuroendocrinology. 2016 Jan;63:271-5. (PMID: 26529050)
      J Endocrinol Invest. 2004 Jul-Aug;27(7):665-9. (PMID: 15505991)
      Brain Behav Immun. 2016 Feb;52:98-105. (PMID: 26456694)
      Cancer Nurs. 2011 Nov-Dec;34(6):470-8. (PMID: 21372704)
      Psychosom Med. 2006 Sep-Oct;68(5):675-83. (PMID: 17012520)
      Int J Impot Res. 2009 Jul-Aug;21(4):207-12. (PMID: 19421198)
      Oncol Nurs Forum. 2013 Mar;40(2):149-56. (PMID: 23448739)
      Brain Behav Immun. 2013 Mar;30 Suppl:S19-25. (PMID: 22728325)
      Psychooncology. 2017 Sep;26(9):1400-1402. (PMID: 27891707)
      J Sex Med. 2013 Feb;10 Suppl 1:102-11. (PMID: 23387915)
      Psychosom Med. 1995 Jul-Aug;57(4):336-44. (PMID: 7480563)
      J Pers Soc Psychol. 1988 Jun;54(6):1063-70. (PMID: 3397865)
      Med Care. 1998 Jul;36(7):1002-12. (PMID: 9674618)
      Behav Neurosci. 2016 Jun;130(3):351-6. (PMID: 26820589)
      Health Qual Life Outcomes. 2009 Nov 13;7:94. (PMID: 19912640)
      Psychoneuroendocrinology. 2017 Mar;77:90-94. (PMID: 28024274)
      Biol Psychol. 2009 Mar;80(3):265-78. (PMID: 19022335)
      J Natl Cancer Inst. 2009 Jun 16;101(12):888-92. (PMID: 19509365)
      Psychoneuroendocrinology. 2014 Nov;49:182-6. (PMID: 25108161)
      Urol Res. 2003 Dec;31(6):402-6. (PMID: 14508617)
    • Grant Information:
      L30 CA136998 United States CA NCI NIH HHS; P30 CA016042 United States CA NCI NIH HHS; SC1 CA187494 United States CA NCI NIH HHS; UL1 TR001863 United States TR NCATS NIH HHS
    • Contributed Indexing:
      Keywords: cortisol; hypothalamic–pituitary–adrenal axis; prostate cancer; sexual bother; sexual functioning
    • Accession Number:
      WI4X0X7BPJ (Hydrocortisone)
    • Publication Date:
      Date Created: 20180427 Date Completed: 20210514 Latest Revision: 20210919
    • Publication Date:
      20231215
    • Accession Number:
      PMC6309533
    • Accession Number:
      10.1177/1359105318772655
    • Accession Number:
      29696999